Market research
34D.F DiaSorin S.p.A
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 4B
- P/E ratio
- 29.59
- Analyst target
- Not available
- Dividend yield
- 1.6%
- Beta
- 0.67
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- IT0003492391
- Market cap
- 4B
- P/E ratio
- 29.59
- Analyst target
- Not available
- Dividend yield
- 1.6%
- Beta
- 0.67
About
About DiaSorin S.p.A
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Research context
DiaSorin S.p.A appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 34D.F discussion.
5 years, 6 months ago
DiaSorin S.p.A is currently in a long term uptrend where the price is trading 0.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.6.
DiaSorin S.p.A's total revenue rose by 49.7% to $271M since the same quarter in the previous year.
Its net income has increased by 74.1% to $85M since the same quarter in the previous year.
Finally, its free cash flow grew by 71.0% to $105M since the same quarter in the previous year.
Based on the above factors, DiaSorin S.p.A gets an overall score of 5/5.